Generation of human myeloid suppressor cells in the in vitro experimental model

封面

如何引用文章

全文:

详细

Myeloid suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that generally differentiate into macrophages, granulocytes, and dendritic cells. However, in pathology, these cells acquire a suppressor phenotype, blocking immune response. In particular, MDSC levels increase in many pathological conditions, including inflammation, sepsis, traumatic shock, autoimmune diseases, cancer, and pregnancy. Over the past 12 years, an interest in examining this cell population has been steadily increased [PUBMED: 2008 (65 articles); 2020 (> 650 entries)] that will expand our understanding of immune system functioning. In humans, MDSCs are characterized by HLA-DR-CD33+CD11b+ phenotype, in turn being subdivided into CD15+ or CD66+ granulocytic (G-MDSC), CD14+ monocytic (M-MDSC), and early (e-MDSC) MDSC bearing HLA-DR-CD11b+CD33+CD14-CD66b- phenotype. This work was aimed to develop an adequate experimental model allowing to evaluate cytokine-driven differentiation of human MDSCs from peripheral blood mononuclear cells in long-term in vitro culture system. For this, peripheral blood mononuclear cells were isolated from healthy donors induced to express MDSC phenotype with GM-CSF and IL-6 (40 or 20 ng/ml) cultured for 7, 14, 21 days. In several experiments, LPS (100 ng/ml) was added to the cultured cells 24 hours before immunophenotyping. The percentage of living Zombie Aquanegative cells in cultures (gated on cells according to FSC/SSC) ranged from 90.5-93.9%. No significant differences were observed between cultured cells. In our experimental conditions, the mean percentage of total MDSC subpopulation reached 2-2.3% of total living cells, exceeding that one by 9-10-fold found in freshly isolated mononuclear cells from healthy subjects. Based on the results of our experimental study, we found that induction of e-MDSC derived from human peripheral blood mononuclear cells requires two weeks of co-culture with 40 ng/ml IL-6 and 40 ng/ml GM-CSF. “Mature” MDSCs (M-MDSC + G-MDSC) yield was peaked in the following conditions: co-culture for 3 weeks with 20 ng/ml IL-6 and 20 ng/ml GM-CSF added with 100 ng/ml LPS 24 hours before completing protocol. Overall, further examining factors modulating MDSC differentiation will reveal conditions necessary for generating this suppressor cell subset potentially used in clinical practice.

作者简介

V. Timganova

Institute of Ecology and Genetics of Microorganisms, Ural Branch, Russian Academy of Sciences, Branch of the Perm Federal Research Center, Ural Branch, Russian Academy of Sciences

编辑信件的主要联系方式.
Email: timganovavp@gmail.com

Timganova Valeriya P. - PhD (Biology), Research Associate, Laboratory of Ecological Immunology

614081, Perm, Golev str., 13

Phone: 7 (902) 836-14-55

俄罗斯联邦

M. Bochkova

Institute of Ecology and Genetics of Microorganisms, Ural Branch, Russian Academy of Sciences, Branch of the Perm Federal Research Center, Ural Branch, Russian Academy of Sciences

Email: fake@neicon.ru

PhD (Biology), Research Associate, Laboratory of Ecological Immunology

Perm

俄罗斯联邦

S. Uzhviyuk

Perm State National Research University

Email: fake@neicon.ru

Student, Microbiology and Immunology Department, Faculty of Biology

Perm

俄罗斯联邦

K. Shardina

Institute of Ecology and Genetics of Microorganisms, Ural Branch, Russian Academy of Sciences, Branch of the Perm Federal Research Center, Ural Branch, Russian Academy of Sciences

Email: fake@neicon.ru

Graduate Student, Laboratory of Ecological Immunology

Perm

俄罗斯联邦

S. Zamorina

Institute of Ecology and Genetics of Microorganisms, Ural Branch, Russian Academy of Sciences, Branch of the Perm Federal Research Center, Ural Branch, Russian Academy of Sciences; Perm State National Research University

Email: fake@neicon.ru

PhD, MD (Biology), Leading Research Associate, Laboratory of Ecological Immunology; Professor, Microbiology and Immunology Department, Faculty of Biology

Perm

俄罗斯联邦

M. Rayev

Institute of Ecology and Genetics of Microorganisms, Ural Branch, Russian Academy of Sciences, Branch of the Perm Federal Research Center, Ural Branch, Russian Academy of Sciences; Perm State National Research University

Email: fake@neicon.ru

PhD, MD (Biology), Leading Research Associate, Laboratory of Ecological Immunology; Professor, Microbiology and Immunology Department, Faculty of Biology

Perm

俄罗斯联邦

参考

  1. Атретханы К.-С.Н., Друцкая М.С. Миелоидные супрессорные клетки и провоспалительные цитокины как мишени терапии рака // Биохимия, 2016. Т. 81, № 11. С. 1520-1529. [Atretkhany K.-S.N., Drutskaya M.S. Myeloid-derived suppressor cells and proinflammatory cytokines as targets for cancer therapy Biokhimiya = Biochemistry, 2016, Vol. 81, no. 11, pp. 1520-1529. (In Russ.)]
  2. Пономарев А.В. Миелоидные супрессорные клетки: общая характеристика // Иммунология, 2016. Т. 37, № 1. С. 47-50. [Ponomarev A.V. Myeloid suppressor cells: general characteristics. Immunologiya = Immunology, 2016, Vol. 37, no. 1, pp. 47-50. (In Russ.)]
  3. Dumitru C.A., Moses K., Trellakis S., Lang S., Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother., 2012, Vol. 61, no. 8, pp. 1155-1167.
  4. Gabrilovich D.I., Nagaraj S. Myeloid- derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 2009, Vol. 9, pp. 162-174.
  5. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol., 2012, Vol. 12, no. 4, pp. 253-268.
  6. Goedegebuure P., Mitchem J.B., Porembka M.R., Tan M.C.B., Belt B.A., Wang-Gillam A., et al. Myeloidderived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr. Cancer Drug Targets, 2011, Vol. 11, no. 6, pp. 734-751.
  7. Greten T.F., Manns M.P., Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol., 2011, Vol. 11, no. 7, pp. 802-807.
  8. Kotsakis A., Harasymczuk M., Schilling B., Georgoulias V., Argiris A., Whiteside T.L. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods, 2012, Vol. 381, pp. 14-22.
  9. Kumar V., Patel S., Tcyganov E., Gabrilovich D.I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol., 2016, Vol. 37, pp. 208-220.
  10. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokineinduced myeloid derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol., 2010, Vol. 185, no. 4, pp. 2273-2284.
  11. Pak V.N. Selective targeting of myeloid-derived suppressor cells in cancer patients through AFP-binding receptors. Future Sci. OA, 2018, Vol. 5, no. 1. doi: 10.4155/fsoa-2018-0029.
  12. Tesi R.J. MDSC; The most important cell you have never heard of. Trends Pharmacol. Sci., 2019, Vol. 40, no. 1, pp. 4-7.
  13. Veglia F., Perego M., Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat. Immunol., 2018, Vol. 19, no. 2, pp. 108-119.

版权所有 © Timganova V.P., Bochkova M.S., Uzhviyuk S.V., Shardina K.Y., Zamorina S.A., Rayev M.B., 2020

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##